Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients

British Journal of Cancer

Volumn 80, Issue 10, 1999, Pages 1648-1651

  Kimura, M ^a   Tomita, Y ^a   Imai, T ^a   Saito, T ^a   Katagiri, A ^a   Tanikawa, T ^a   Takeda, M ^a   Takahashi, K ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

Prognosis; Renal cell cancer; Soluble CD95 (Fas APO 1)

Indexed keywords

FAS ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; KIDNEY CANCER; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

EID: 0033064690     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690576     Document Type: Article

References (15)

1. Albanese J, Meterissian S, Kontogiannea M, Dubreuil C, Hand A, Sorba S and Dainiak N (1998) Biologically active Fas antigen and its cognate are expressed in plasma membrane-derived extracellular vesicles. Blood 91: 3862-3874
2. Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T and Thompson CB (1995) CD28 costimulation can promote T cell survival by enhancing the expression and Bcl-xL. Immunity 3: 87-98
3. Cheng J, Zhou T, Liu C, Shapiro JP, Bruer MJ, Kiefer MC, Barr PJ and Mountz JD (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263: 1759-1762
4. Fellenberg J, Mau H, Schhuerpflung C, Ewerbeck and Debatin KM (1997) Modulation of resistance to anti-APO-1-induced apopotosis in osteosarcoma cells by cytokines. Int J Cancer 72: 536-542
5. Hu S, Vincenz C, Ni J, Gentz R and Dixit VM (1997) I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1-and CD-95-induced apoptosis. J Biol Chem 272: 17255-17257
6. Japanese Urological Association, Japanese Pathological Society and Japanese Radiological Society (1992) General Rule for Clinical and Pathological Studies on Renal Cell Carcinoma. 2nd Edition, Aso Y. (ed) Kanehara-Shuppan: Tokyo
7. Jodo S, Kobayashi S, Kayagaki N, Ogura Y, Feng Y, Amasaki Y, Fujisaku A, Azuma M, Yagita H, Okumura K and Koike T (1997) Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol 107: 89-95
8. Knipping E, Debatin K M, Stricker K, Heilig B, Eder A and Krammer PH (1995) Identification of soluble APO-1 in supernatants of human B-and T-cell lines and increased serum levels in B-and T-cell leukemias. Blood 85: 1562-1569
9. Lanigan D (1995) Prognostic factors in renal cell carcinoma. Br J Urol 75: 565-571
10. Midis GP, Shen Y and Owen-Schaub LB (1996) Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res 56: 3870-3874
11. Nagata S (1994) Fas and Fas ligand: a death factor and its receptor. Adv Immunol 57: 129-144
12. Nonomura N, Miki T, Yokoyama M, Imazuy T, Takeda T, Takeuchi S, Kanno N, Nishimura K, Kojima Y and Okuyama A (1996) Fas/APO-1-mediated apoptosis of human renal cell cancer, Biochem Biophys Res Com 229: 945-951
13. Owen-Schaub LB, Angelo LS, Radinsky R, Warew CF, Gesner TG, Bartos DP (1995) Soluble Fas/Apo-1 in tumor cells: a potencial regulator of apoptosis? Cancer Lett 94: 1-8
14. Tomita Y, Kawasaki T, Bilim V, Takeda M and Takahashi K (1996a) Tetrapeptide DEVD aldehyde or YVAD-chloromethylketone inhibits Fas/Apo-1 (CD95)-mediated apoptosis in renal-cell-cancer cells. Int J Cancer 68: 132-135
15. Tomita Y, Bilim V, Kawasaki T, Takeda M, Takahashi K, Ismail O, Magnusson K and Wiman K (1996b) Frequent expression of bel-2 in renal-cell carcinomas carring wild-type p53. Int J Cancer 66: 322-325